These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 20006497)
21. In search of AKT kinase inhibitors as anticancer agents: structure-based design, docking, and molecular dynamics studies of 2,4,6-trisubstituted pyridines. Trejo-Soto PJ; Hernández-Campos A; Romo-Mancillas A; Medina-Franco JL; Castillo R J Biomol Struct Dyn; 2018 Feb; 36(2):423-442. PubMed ID: 28150530 [TBL] [Abstract][Full Text] [Related]
22. Preparation and evaluation of deconstruction analogues of 7-deoxykalafungin as AKT kinase inhibitors. Korwar S; Nguyen T; Ellis KC Bioorg Med Chem Lett; 2014 Jan; 24(1):271-4. PubMed ID: 24321345 [TBL] [Abstract][Full Text] [Related]
23. Rapid assembly of diverse and potent allosteric Akt inhibitors. Wu Z; Robinson RG; Fu S; Barnett SF; Defeo-Jones D; Jones RE; Kral AM; Huber HE; Kohl NE; Hartman GD; Bilodeau MT Bioorg Med Chem Lett; 2008 Mar; 18(6):2211-4. PubMed ID: 18296048 [TBL] [Abstract][Full Text] [Related]
24. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension. Zhu GD; Gandhi VB; Gong J; Thomas S; Woods KW; Song X; Li T; Diebold RB; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Bouska J; Olson A; Marsh KC; Stoll VS; Mamo M; Polakowski J; Campbell TJ; Martin RL; Gintant GA; Penning TD; Li Q; Rosenberg SH; Giranda VL J Med Chem; 2007 Jun; 50(13):2990-3003. PubMed ID: 17523610 [TBL] [Abstract][Full Text] [Related]
25. Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase. Thomas SA; Li T; Woods KW; Song X; Packard G; Fischer JP; Diebold RB; Liu X; Shi Y; Klinghofer V; Johnson EF; Bouska JJ; Olson A; Guan R; Magnone SR; Marsh K; Luo Y; Rosenberg SH; Giranda VL; Li Q Bioorg Med Chem Lett; 2006 Jul; 16(14):3740-4. PubMed ID: 16678413 [TBL] [Abstract][Full Text] [Related]
26. Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B. Collins I; Caldwell J; Fonseca T; Donald A; Bavetsias V; Hunter LJ; Garrett MD; Rowlands MG; Aherne GW; Davies TG; Berdini V; Woodhead SJ; Davis D; Seavers LC; Wyatt PG; Workman P; McDonald E Bioorg Med Chem; 2006 Feb; 14(4):1255-73. PubMed ID: 16249095 [TBL] [Abstract][Full Text] [Related]
32. Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model. Han W; Menezes DL; Xu Y; Knapp MS; Elling R; Burger MT; Ni ZJ; Smith A; Lan J; Williams TE; Verhagen J; Huh K; Merritt H; Chan J; Kaufman S; Voliva CF; Pecchi S Bioorg Med Chem Lett; 2016 Feb; 26(3):742-746. PubMed ID: 26774655 [TBL] [Abstract][Full Text] [Related]
33. Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure. Okawa T; Aramaki Y; Yamamoto M; Kobayashi T; Fukumoto S; Toyoda Y; Henta T; Hata A; Ikeda S; Kaneko M; Hoffman ID; Sang BC; Zou H; Kawamoto T J Med Chem; 2017 Aug; 60(16):6942-6990. PubMed ID: 28699740 [TBL] [Abstract][Full Text] [Related]
34. 2-Aminomethylthieno[3,2-d]pyrimidin-4(3H)-ones bearing 3-methylpyrazole hinge binding moiety: Highly potent, selective, and time-dependent inhibitors of Cdc7 kinase. Kurasawa O; Homma M; Oguro Y; Miyazaki T; Mori K; Uchiyama N; Iwai K; Ohashi A; Hara H; Yoshida S; Cho N Bioorg Med Chem; 2017 Jul; 25(14):3658-3670. PubMed ID: 28533114 [TBL] [Abstract][Full Text] [Related]
35. Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. Zhao Z; Leister WH; Robinson RG; Barnett SF; Defeo-Jones D; Jones RE; Hartman GD; Huff JR; Huber HE; Duggan ME; Lindsley CW Bioorg Med Chem Lett; 2005 Feb; 15(4):905-9. PubMed ID: 15686884 [TBL] [Abstract][Full Text] [Related]
36. Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors. Terao Y; Suzuki H; Yoshikawa M; Yashiro H; Takekawa S; Fujitani Y; Okada K; Inoue Y; Yamamoto Y; Nakagawa H; Yao S; Kawamoto T; Uchikawa O Bioorg Med Chem Lett; 2012 Dec; 22(24):7326-9. PubMed ID: 23147077 [TBL] [Abstract][Full Text] [Related]
37. Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension. Shaw D; Hollingworth G; Soldermann N; Sprague E; Schuler W; Vangrevelinghe E; Duggan N; Thomas M; Kosaka T; Waters N; van Eis MJ Bioorg Med Chem Lett; 2014 Oct; 24(20):4812-7. PubMed ID: 25248678 [TBL] [Abstract][Full Text] [Related]
38. Structure-based optimization and biological evaluation of trisubstituted pyrazole as a core structure of potent ROS1 kinase inhibitors. Park BS; Al-Sanea MM; Abdelazem AZ; Park HM; Roh EJ; Park HM; Yoo KH; Sim T; Tae JS; Lee SH Bioorg Med Chem; 2014 Aug; 22(15):3871-8. PubMed ID: 24997577 [TBL] [Abstract][Full Text] [Related]
39. The identification of 8,9-dimethoxy-5-(2-aminoalkoxy-pyridin-3-yl)-benzo[c][2,7]naphthyridin-4-ylamines as potent inhibitors of 3-phosphoinositide-dependent kinase-1 (PDK-1). Nittoli T; Dushin RG; Ingalls C; Cheung K; Floyd MB; Fraser H; Olland A; Hu Y; Grosu G; Han X; Arndt K; Guo B; Wissner A Eur J Med Chem; 2010 Apr; 45(4):1379-86. PubMed ID: 20074837 [TBL] [Abstract][Full Text] [Related]
40. Azole-based inhibitors of AKT/PKB for the treatment of cancer. Zeng Q; Allen JG; Bourbeau MP; Wang X; Yao G; Tadesse S; Rider JT; Yuan CC; Hong FT; Lee MR; Zhang S; Lofgren JA; Freeman DJ; Yang S; Li C; Tominey E; Huang X; Hoffman D; Yamane HK; Fotsch C; Dominguez C; Hungate R; Zhang X Bioorg Med Chem Lett; 2010 Mar; 20(5):1559-64. PubMed ID: 20137943 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]